In April 2003, Jiangsu Simcere Pharmaceutical Co., Ltd. and Simcere Pharmaceutical Co., Ltd. were recognized by the Ministry of Science and Technology as the “Key High-tech Enterprises of the National Torch Plan”

2003 In December 2004, with the approval of the Ministry of Personnel, Simcere Pharmaceuticals established a corporate postdoctoral research station

In February 2004, Zailin was officially recognized as a well-known trademark in China by the Trademark Office of the State Administration for Industry and Commerce

In January 2006, Simcere Pharmaceutical Co., Ltd. was jointly recognized as a "Nationally Recognized Enterprise Technology Center" by the Ministry of Science and Technology, the National Development and Reform Commission, the Ministry of Finance, the General Administration of Customs, and the State Administration of Taxation. The quasi-new drug "Zaichang" tablets won the second prize of the 2005 National Science and Technology Progress Award

In February 2007, Simcere Pharmaceutical Co., Ltd. won the title of "Top 500 Chinese Enterprises in Information Technology in 2006"

In June 2007, Simcere Pharmaceuticals won the title of the 7th "Future Star-The Most Promising Emerging Enterprise"

In February 2008, Simcere Pharmaceuticals won the title of Nanjing Municipal Party Committee , the title of "Spiritual Civilization Unit" awarded by the municipal government in 2005-2006.

In January 2008, Simcere Pharmaceuticals' invention patent "Method for Producing Endostatin" for the anti-tumor biological drug Endostatin won the 10th China Patent Gold Award. On February 3, 2008, Simcere Pharmaceutical's brand product Yingtaiqing was officially awarded the title of "China's Well-known Trademark"

On March 23, 2008, Simcere Pharmaceutical was awarded the CECA National Informatization Assessment The honorary title of "Top 500 Chinese Enterprises in Informatization in 2007" issued by the Center. On April 2, 2008, Simcere Pharmaceuticals was awarded the title of "Nanjing Outstanding Private Enterprise in 2007" by the Nanjing Leading Group for the Development of Private Individual Economy

In April 2008, Simcere Pharmaceuticals' cardiovascular brand generic drug Bicun (Edaravone Injection) was recognized by the Jiangsu Provincial Department of Science and Technology as one of the first batch of high-tech products in Jiangsu Province in 2008, and obtained High-tech product certification issued by the Department of Science and Technology.

On September 21, 2008, Simcere Pharmaceuticals won the 2008 Chinese Pharmaceutical Enterprises "Corporate Social Responsibility Excellence Award" jointly issued by the China Pharmaceutical Enterprise Management Association and the People's Daily Network Center.

On October 31, 2008, Simcere Pharmaceuticals was selected into the "Star 50" list of China's new business forces by "Entrepreneur" magazine.

On November 20, 2008, Simcere Pharmaceuticals was selected into the "Top 500 Global Chinese High-tech Enterprises in 2008" by the World Chinese Entrepreneurs Association, ranking 276th in the global Chinese Entrepreneurs Ranking.

On January 9, 2009, Simcere Pharmaceuticals’ scientific research project “Drug Design, Kilogram-level Preparation Technology and Clinical Application of New Vascular Inhibitor Anti-tumor Drugs” for Endu, an anti-tumor biological drug, won the first prize. *The second prize of the 2008 National Technological Invention Award issued by the Central Committee and the State Council.

On January 17, 2009, the Sixth Member (Director) Conference of the China Pharmaceutical Enterprise Management Association and the Award Ceremony of the 30 Years of Chinese Medicine were held in Beijing. Simcere Pharmaceuticals won the "Innovation Award" of the China Pharmaceutical 30 Years Conference.

In August 2010, "Zailin" won the honor of being listed in the "Healthy China 2010 Chinese Pharmaceutical Brand List"